Drug intelligence / Profile preview

lerociclib + osimertinib

Development stage: Unknown
Lead developer: G1 Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Lerociclib (G1T38) + osimertinib (Tagrisso) is a combination therapy being investigated for EGFR mutation-positive non-small cell lung cancer (NSCLC). Lerociclib is an oral CDK4/6 inhibitor designed to stop cancer cell growth by inhibiting the enzymes CDK4 and CDK6, which are involved in cell cycle progression. Osimertinib is an irreversible EGFR tyrosine kinase inhibitor that blocks EGFR-sensitizing and EGFR T790M-resistance mutations. The combination aims to enhance efficacy and potentially overcome resistance mechanisms in patients who have progressed on first-line EGFR inhibitors.

Other names: lerociclib + Tagrisso

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on lerociclib + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lerociclib + osimertinib.

Explore the full profile